OrthoPediatrics (NASDAQ:KIDS) Stock Rating Upgraded by TD Cowen

OrthoPediatrics (NASDAQ:KIDS) was upgraded by analysts at TD Cowen to a “strong-buy” rating in a research report issued on Tuesday,Zacks.com reports.

Other research analysts have also recently issued research reports about the stock. Piper Sandler cut their price objective on shares of OrthoPediatrics from $30.00 to $22.00 and set an “overweight” rating on the stock in a research report on Friday, October 10th. Wall Street Zen raised shares of OrthoPediatrics from a “sell” rating to a “hold” rating in a research note on Saturday, January 17th. BTIG Research reiterated a “buy” rating and set a $23.00 price target on shares of OrthoPediatrics in a report on Wednesday, October 29th. Stifel Nicolaus decreased their price objective on shares of OrthoPediatrics from $32.00 to $20.00 and set a “buy” rating for the company in a research note on Friday, October 10th. Finally, Lake Street Capital dropped their target price on OrthoPediatrics from $37.00 to $34.00 and set a “buy” rating for the company in a research report on Friday, October 10th. One equities research analyst has rated the stock with a Strong Buy rating, eight have given a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average price target of $23.89.

OrthoPediatrics Trading Down 2.4%

Shares of KIDS stock opened at $17.32 on Tuesday. The company has a market cap of $434.39 million, a PE ratio of -8.88 and a beta of 1.09. OrthoPediatrics has a 1 year low of $15.28 and a 1 year high of $26.40. The stock’s 50 day simple moving average is $18.08 and its two-hundred day simple moving average is $18.79. The company has a debt-to-equity ratio of 0.28, a current ratio of 7.40 and a quick ratio of 3.52.

OrthoPediatrics (NASDAQ:KIDS) last released its earnings results on Tuesday, October 28th. The company reported ($0.24) earnings per share for the quarter, beating the consensus estimate of ($0.26) by $0.02. OrthoPediatrics had a negative return on equity of 6.86% and a negative net margin of 20.06%.The firm had revenue of $61.25 million for the quarter, compared to the consensus estimate of $63.63 million. Research analysts predict that OrthoPediatrics will post -0.93 earnings per share for the current year.

Institutional Trading of OrthoPediatrics

Institutional investors and hedge funds have recently modified their holdings of the stock. Prosight Management LP boosted its holdings in shares of OrthoPediatrics by 319.2% in the third quarter. Prosight Management LP now owns 308,707 shares of the company’s stock valued at $5,720,000 after purchasing an additional 235,060 shares during the period. Millennium Management LLC raised its position in OrthoPediatrics by 55.3% during the 1st quarter. Millennium Management LLC now owns 656,578 shares of the company’s stock valued at $16,172,000 after purchasing an additional 233,873 shares in the last quarter. Deerfield Management Company L.P. lifted its holdings in shares of OrthoPediatrics by 1,153.4% in the 3rd quarter. Deerfield Management Company L.P. now owns 194,109 shares of the company’s stock worth $3,597,000 after buying an additional 178,623 shares during the period. Goldman Sachs Group Inc. lifted its holdings in shares of OrthoPediatrics by 112.3% in the 1st quarter. Goldman Sachs Group Inc. now owns 200,439 shares of the company’s stock worth $4,937,000 after buying an additional 106,041 shares during the period. Finally, Marshall Wace LLP grew its position in shares of OrthoPediatrics by 17.8% during the 2nd quarter. Marshall Wace LLP now owns 419,129 shares of the company’s stock worth $9,003,000 after buying an additional 63,345 shares in the last quarter. Institutional investors own 69.05% of the company’s stock.

OrthoPediatrics Company Profile

OrthoPediatrics Corp., founded in 2007 and headquartered in Warsaw, Indiana, is a medical device company dedicated exclusively to providing orthopedic solutions for children. The company focuses on developing, manufacturing and marketing a broad portfolio of implants and instruments designed to address a wide range of pediatric conditions, including trauma, deformity correction, spine disorders and sports injuries.

The company’s product lines include locking plates and screws for upper and lower extremity reconstruction, intramedullary nails for femur and tibia stabilization, and specialized systems such as the MAGEC Magnetic Growth Rod for treatment of early-onset scoliosis.